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Introduction
Bone metabolism is regulated by the balance between
bone resorption by osteoclasts and bone formation 
by osteoblasts. Estrogen deficiency during menopause 
is associated with an increased rate of bone loss.
However, the mechanism responsible for the effects of
estrogen on osteoclasts is still unclear. Some reports
suggest that estrogen inhibits bone resorption by mature
isolated osteoclasts [1,2], whereas other studies have
failed to detect such an effect [3,4].
A substantial body of evidence suggests that estrogen
withdrawal following menopause leads to an increase
in the production of hematopoietic growth factors, such
as granulocyte-macrophage colony-stimulating factor
and macrophage colony-stimulating factor (M-CSF),
and proinflammatory cytokines, including interleukin 1,
interleukin 6, and tumor necrosis factor from the
stroma, monocytes and lymphoid cells [5–7]. Elevated
levels of these factors are believed to stimulate the dif-
ferentiation of myeloid precursor cells into osteoclasts
[8]. Estrogen therapy suppresses the expression of these
osteoclastogenic cytokines and reduces osteoclast for-
mation [9,10]. This reduction in cytokine expression and
a concomitant reduction in osteoclast formation have
been suggested to account for at least part of estrogen’s
beneficial effects in preventing postmenopausal osteo-
porosis. These results suggest that estrogen could influ-
ence osteoclast formation, differentiation and activity.
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SUMMARY
Objective: Estrogen deficiency results in postmenopausal osteoporosis by increasing the rate of bone loss. 
The mechanism responsible for the effects of estrogen on osteoclasts is still unclear.
Materials and Methods: The potential of mononuclear cells from cord blood or bone marrow to differentiate
into mature osteoclasts when co-cultured with human osteoblast cells was investigated. The effects of estrogen
on osteoclastogenesis and osteoclast activity were also examined.
Results: Macrophage markers CD11b and CD14 were downregulated and vitronectin receptor was upregulated
during 28 days’ co-culture of mononuclear cells and human osteoblasts. Long-term co-culture resulted in the
formation of numerous large tartrate-resistant acid phosphatase-positive multinucleated cells capable of
resorption of bone slices. After incubation for 28 days, the addition of 17β-estradiol caused a significant
decrease in the expression of vitronectin receptor and tartrate-resistant acid phosphatase-positive multinucle-
ated cells in cultures derived from both bone marrow and cord blood. A significant decrease in bone resorption
was also noted in the presence of estrogen.
Conclusion: Estrogen not only suppresses osteoclastogenesis but also inhibits the activity of osteoclasts.
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In this study, we investigated the ability of mononu-
clear macrophages derived from cord blood or bone
marrow to differentiate into mature osteoclasts when
co-cultured with human osteoblasts. We further exam-
ined the effects of estrogen on osteoclastogenesis and
osteoclast activity during culture.
Materials and Methods
Primary culture of human osteoblasts
Human bone samples were obtained during orthope-
dic procedures from the upper femur of patients with
no evidence of metabolic bone disease, following ethi-
cal approval. Bone explants were cultured according
to a previously described method [11]. Connective tis-
sue was carefully dissected from the bone fragments,
which were then extensively washed with phosphate-
buffered saline (PBS) and diced into small pieces
(3–5 mm in diameter) using a scalpel. The PBS was
decanted off, and the bone chips were transferred to 
a 50-mL polypropylene tube containing 15–20 mL of
PBS. The tube was vortexed vigorously three times for
10 seconds, and then left to stand for 30 seconds to
allow the bone fragments to settle. The supernatant
containing hematopoietic tissue and dislodged cells
was then decanted off. An additional 15–20 mL of PBS
was added, and the bone fragments were vortexed as
before. This process was repeated a minimum of three
times, or until no remaining hematopoietic marrow
was visible and the bone fragments assumed a white,
ivory-like appearance.
The bone fragments were then digested for 2 hours
at 37°C in a shaking water bath with crude bacterial
collagenase at 1 mg/mL in Dulbecco’s modified Eagle’s
medium (GIBCO, Maryland, NY, USA). The fragments
were seeded into 75-cm2 culture flasks and cultured in
a calcium-free, phenol red-free medium (GIBCO) con-
sisting of a 1:1 mixture of penicillin and streptomycin
(100 U/mL and 100 μg/mL, respectively; GIBCO). The
medium was replaced with an equal volume (10 mL)
of fresh medium each week for the first 2 weeks and
then twice weekly thereafter. At least 60% of the cells 
in all the cultures showed intense staining for alkaline
phosphatase activity. Trypan blue was used to screen out
dead cells after harvesting. The cultures were grown to
confluence for about 4–6 weeks and were then passaged
for experimentation.
Isolation of mononuclear cells from bone marrow and
cord blood
Human mononuclear cells were isolated from the cord
blood of healthy volunteers (n = 10) using Ficoll-Paque
(Biochrom AG, Berlin, Germany) sedimentation and
adherence. Each 4 mL of blood collected was diluted
1:1 with Eagle’s minimal essential medium (αMEM)
(Invitrogen, Carlsbad, CA, USA), layered with 5 mL of
Ficoll-Paque, and centrifuged at 510g for 20 minutes.
The mononuclear cell-rich layer at the interface was
removed and washed twice in αMEM, and the pellet
was then resuspended in αMEM supplemented with 10%
fetal calf serum (FCS), 100 U/mL penicillin, 100 μg/mL
streptomycin sulfate, and 2 mM L-glutamine. The num-
ber of cells in the cell suspension was finally counted 
in a hemocytometer after lysis of the red blood cells
using a 5% (vol/vol) acetic acid solution. Bone marrow
was aspirated from the iliac bone of patients (n = 10)
undergoing bone graft surgery. The bone marrow cells
were washed twice in αMEM, and the pellet was res-
uspended in αMEM supplemented with 10% FCS,
100 U/mL penicillin, 100 μg/mL streptomycin sulfate,
and 2 mM L-glutamine. The cell suspension was counted
in a hemocytometer after lysis of the red blood cells
using a 5% (vol/vol) acetic acid solution.
Preparation of co-cultures on coverslips and 
bone slices
The monocyte/macrophage cell suspensions from cord
blood or bone marrow were added to the 7-mm wells
containing coverslips or bone slices seeded 48 hours
earlier with human osteoblast-like cells. The cells were
allowed to adhere for 1 hour at 37°C in 5% CO2, and
the coverslips and bone slices were then removed from
the wells, washed vigorously in αMEM to remove non-
adherent cells and placed in larger 16-mm wells contain-
ing 1 mL of αMEM/FCS. These cultures were incubated
for 28 days in the presence of 10−7M 1,25 (OH)2D3,
10−8M dexamethasone, and 25 ng/mL M-CSF, with or
without 10−8M 17β-estradiol (E2). The culture medium
was changed every 3–4 days.
Analysis of cell cultures for macrophage and 
osteoclast phenotypic markers and effects of 
estrogen on osteoclast formation
The coverslips were removed from the co-cultures with
and without 17β-E2 after incubation for 24 hours and
for 14 days and stained histochemically for the expres-
sion of tartrate-resistant acid phosphatase (TRAP), 
an osteoclast-associated marker, using a commercially
available kit (Sigma-Aldrich, St. Louis, MO, USA). The
cells were fixed in citrate/acetone solution and stained
for acid phosphatase, with naphthol AS-BI phosphate
as a substrate, in the presence or absence of 1.0 M tar-
trate; the product was reacted with Fast Garnet GBC
salt. The cell preparations were then counterstained
with hematoxylin. Cell preparations on coverslips were
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also stained immunohistochemically using an indirect
immunoperoxidase method with monoclonal antibodies
BEAR1 and RMO52 (Coulter Immunotech, Marseille,
France). These detected expression of the macrophage-
associated antigens, CD11b and CD14, respectively,
both of which are known not to be expressed by osteo-
clasts, while a monoclonal anti-vitronectin antibody
(Sigma-Aldrich) was used to determine the expression of
the vitronectin receptor (VNR), an osteoclast-associated
antigen. When used in conjunction with lacunar bone
resorption, VNR expression is an essential indicator of
osteoclast differentiation.
Functional evidence of osteoclast differentiation and
effects of estrogen on bone resorption
After 28 days’ culture, the cortical bone slices on which
human cord blood monocytes/bone marrow cells and
human osteoblast-like cells had been cultured (with and
without 17β-E2) were removed from the wells, rinsed
in PBS, and trypsinized for 15 minutes to remove the
stromal cell layer. They were then washed vigorously in
distilled water and left overnight in 0.25% ammonium
hydroxide to remove the remaining adherent cells. After
rinsing in distilled water, the bone tissues were pre-fixed
with 1% glutaraldehyde (Electron Microscopy Science,
Fort Washington, PA, USA) and 3% paraformaldehyde
(Electron Microscopy Science) in 0.1M phosphate
buffer (pH 7.4) for 3 hours and then post-fixed with
1% osmium tetroxide (Electron Microscopy Science,
Fort Washington, PA, USA) in the same buffer for 
2 hours. After dehydrating in an ethanol series, critical-
point drying and coating with gold, the bone slices were
examined by scanning electron microscopy (Hitachi 
S-2400; Hitachi, Tokyo, Japan).
Results
Development of osteoclasts from bone marrow and
cord blood in co-culture with osteoblasts
Human osteoblasts and mononuclear macrophages
derived from cord blood or bone marrow were co-
cultured for 28 days. The expression of the macrophage
cell-surface antigens, CD11b and CD14, was strong
during the first 14 days and decreased progressively
thereafter (Figures 1A and 1B). During the first 14
days, the co-cultures were largely negative for VNR, an
osteoclast-associated antigen, and TRAP-positive multi-
nucleated cells. VNR expression increased progressively
from day 14 to day 28 of co-culture (Figure 1C).
Although CD11b and CD14 were downregulated and
VNR was upregulated in the osteoclasts differentiated
from both cord blood and bone marrow cells at 28
days, their expression was more prominent in the cul-
tures derived from cord blood than in those from bone
marrow (Figure 1).
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Figure 1. Time course of changes in the expression of the
macrophage cell-surface antigens, CD11b and CD14, and
osteoclast-associated antigen, vitronectin receptor, during
28 days’ co-culture of human osteoblasts and mononuclear
macrophages derived from cord blood or bone marrow. The
percentages of cells expressing (A) CD11b, (B) CD14 and
(C) vitronectin receptor were determined by flow cytometric
analysis. Results are presented as mean ± standard error of the
mean of three independent experiments (n = 10). BM = bone
marrow; CB = cord blood; VNR = vitronectin receptor.
Taiwan J Obstet Gynecol • December 2009 • Vol 48 • No 4 353
Estrogen Inhibits Osteoclastic Activity
Effects of estrogen on osteoclastogenesis and 
osteoclast activity
The addition of 17β-E2 after 28 days’ incubation caused
a significant decrease in VNR expression (Figure 2A)
and TRAP-positive multinucleated cells (Figure 2B) in
cultures derived from both bone marrow and cord
blood cells. Compared with the cultures without 17β-E2,
the extent of bone resorption on bone slices was also
decreased in the presence 17β- E2 in the 28-day cultures
(Figure 3).
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Figure 2. 17β-estradiol (E2) inhibited the development of osteoclasts. The expression of (A) vitronectin receptor and (B) tartrate-
resistant acid phosphatase-positive multinucleated cells were evaluated after co-culture of human osteoblasts and mononu-
clear macrophages derived from cord blood or bone marrow with or without 17β-E2 for 28 days. The percentage of cells
expressing vitronectin receptor was determined by flow cytometric analysis. Results are presented as mean ± standard error of
the mean of three independent experiments (n = 10). BM = bone marrow; CB = cord blood; TRAP = tartrate-resistant acid
phosphatase; VNR = vitronectin receptor.
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Figure 3. (A) Culture with 17β-estradiol (E2), day 14; (B) culture with 17β-E2, day 28; (C) culture without 17β-E2, day 14; 
(D) culture without 17β-E2, day 28. The extent of bone resorption on the cortical bone slices incubated in co-cultures of
human osteoblasts and mononuclear macrophages derived from cord blood or bone marrow, with or without 17β-E2 for 
28 days. Distinctive excavations were noted in the bone surface in the cultures (A, B) with and (C, D) without 17β-E2.
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Discussion
In this study, we used an in vitro osteoclast formation
model and found that mononuclear osteoclast precur-
sors were present in both the bone marrow and cord
blood. Co-culture with human osteoblasts was found
to support the formation of human osteoclasts. Cells
isolated from bone marrow and cord blood initially
expressed a predominantly macrophage phenotype. After
long-term co-culture with human osteoblasts, the expres-
sion of VNR and TRAP-positive multinucleated cells
increased. In addition, we found that estrogen not only
suppressed osteoclastogenesis in bone marrow and cord
blood, but also inhibited bone resorption by osteoclasts.
Cells from bone marrow and cord blood expressed
the macrophage markers CD11b and CD14, which were
downregulated during the differentiation of osteoclasts.
The expression of VNR, an osteoclast-associated anti-
gen, was upregulated during osteoclast differentiation.
These results clearly indicate that cells from the bone
marrow and cord blood are both macrophages and
progenitors of osteoclasts. However, during osteoclast
formation, we found that the expression of CD11b
and CD14 in the first 14 days of co-culture, and also
the expression of VNR after 28-days’ co-culture, were
more prominent in cells from cord blood than in those
from bone marrow. It is possible that there are fewer
osteoclast precursors in bone marrow than in cord
blood. Some reports have shown that approximately
4.3–5% of bone marrow cells respond to M-CSF [12,13]
and, therefore, represent osteoclast progenitors.
Estrogen deficiency is responsible for increased bone
turnover during the menopausal period. Kawamoto et al
[14] demonstrated that the number of TRAP-positive
cells in the rat periodontium was significantly higher in
ovariectomized rats than in intact rats, or in ovariectomi-
zed rats treated with 17β-E2. They, therefore, suggested
that estrogen deficiency induced osteoclastogenesis 
in the rat periodontium and that quantitative changes
in osteoclastogenesis could be prevented by estradiol
infusion. In the present study, estrogens suppressed
the expression of VNR and TRAP-positive multinucle-
ated cells in both bone marrow cell- and cord blood
cell-derived cultures for 28 days. Similar results were
also reported by Ramalho et al [15], who found that
17β-E2 and raloxifene significantly decreased the num-
ber of TRAP-positive multinucleated cells produced by
bone marrow cells cultured for 15 days. This suggests
not only that estrogens suppress osteoclastogenesis
but also that osteoclast precursors are direct targets 
of estrogen action. The mechanism of regulation of
osteoclastogenesis by estrogens has been evaluated 
in some studies [16,17], which showed that estrogen
downregulated osteoclastogenesis by directly decreas-
ing the responsiveness of osteoclast precursors to osteo-
clastogenic factors. However, in the present study, we
found that estrogens did not interfere with the process
of osteoclast formation from precursors in the bone
marrow and cord blood.
It is well established that estrogens play a central
role in the regulation of bone resorption by osteoclasts.
However, the mechanism by which estrogens exert their
effects on osteoclasts is not known. The aforementioned
results suggest that estrogens could inhibit bone resorp-
tion by reducing osteoclast formation, as indicated by
suppression of VNR expression and reductions in the
numbers of TRAP-positive multinucleated cells in the
cultures. Whether or not estrogen directly interferes
with the bone resorptive process of mature osteoclasts
remains controversial. In the present study, the extent
of bone resorption on bone slices was obviously sup-
pressed in the presence of estrogens, compared with
the level of resorption in cultures without estrogens. 
In long-term cultures, although the expression of VNR
was increased, bone resorption on bone slices was still
suppressed in the presence of estrogens. Sarma et al
[18] suggested that estradiol inhibits bone resorption
by reducing the number of osteoclasts, but does not
exert its effect directly on mature osteoclasts. The study
by Sarma et al [18] used bone marrow cultures derived
from both healthy men and postmenopausal women,
and further studies are needed to evaluate the effects
of sex on estrogen-induced effects.
In conclusion, estrogen prevents bone loss through
multiple effects on bone cells and their precursors, result-
ing in decreased osteoclast formation and a reduced
capacity of mature osteoclasts to resorb bone. Further
studies are needed to investigate changes in the bone
microenvironment in women with early postmenopausal
bone loss or postmenopausal osteoporosis.
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